The European Medicines Agency argued that drug development should focus on generating robust evidence rather than adhering to a rigid default on the number of pivotal trials. In an editorial response to “one pivotal study” arguments, EMA executive director Emer Cooke and colleagues said strict trial-count requirements could undermine the aims of clinical evidence generation. EMA’s stance references the FDA’s newer positions on evidence packages and the earlier “two trial dogma” reversal discussed by FDA leadership. EMA said replication can explore effects across different groups and settings, not just provide duplicate confirmation. The messaging is aimed at sponsor strategy, pushing developers to defend study designs based on what evidence is needed for decision-making rather than conforming to a fixed numerical rule. For the biotech community, the editorial signals continuing divergence in how regulators and policy leaders frame evidence thresholds—an issue that can affect trial planning, timelines, and development risk.